Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Imaging, Diagnosis, Prognosis

Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival

Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel and Glen Kristiansen
Wilko Weichert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Denkert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mick Burkhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tserenchunt Gansukh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Bellach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Altevogt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manfred Dietel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glen Kristiansen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-05-0606 Published September 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: CD24 is a cell adhesion molecule that has been implicated in metastatic tumor progression of various solid tumors. We aimed to clarify the expression patterns of CD24 in colorectal cancer and to correlate these to clinicopathologic variables including patient survival.

Experimental Design: 147 colorectal carcinomas and two colon carcinoma cell lines were immunostained for CD24. Cytoplasmic and membranous immunoreactivity were semiquantitatively scored. Fisher's exact test, χ2 test for trends, Kaplan-Meier analysis, and Cox's regression were applied.

Results: The cell line CX-2 showed only a minimal membranous CD24 immunoreactivity, in contrast to HT29, which stained strongly in the cytoplasm. In colorectal cancer, 68.7% of the tumors showed membranous CD24 staining, whereas 84.4% showed cytoplasmic staining. In 10% of cases, an exceptionally strong cytoplasmic CD24 expression was observed. The latter significantly correlated to higher tumor stages (Dukes and pT), nodal or systemic metastasis, and higher tumor grade. In survival analysis, strong cytoplasmic CD24 expression correlated significantly (Cox's regression: P = 0.012, relative risk = 3.7) to shortened patient survival in the group of cases without distant metastases.

Conclusions: CD24 is commonly up-regulated in colorectal cancer and is a new independent prognostic marker which corroborates the importance of CD24 in tumor progression of this disease.

  • CD24
  • Colorectal Cancer
  • Immunohistochemistry
  • Prognosis

Colorectal cancer is the third most common cause of death from cancer in both sexes in the western world and its high incidence has been stable in the last 20 years (1). Although this disease is surgically curable in early stages, the tumor frequently does not become symptomatic before the metastatic stage, which is associated with high mortality. Therefore, increasing efforts are being made to develop more effective screening and prevention strategies for colorectal cancer and to enhance our capabilities to predict the clinical outcome. Currently, the most important conventional prognostic factors for patient survival are histologic tumor grade and tumor stage at time of diagnosis [pathologic tumor-node-metastasis (Unio Internationale Contra Cancrum), Astler-Coller or Dukes], including depth of tumor invasion, involvement of regional lymph nodes, and metastatic spread to distant organs. In addition to these clinicopathologic variables, molecular markers are being evaluated and established for a wide variety of tumors including colon cancer (2). These new markers are being examined for their diagnostic and prognostic effect or even therapeutic implications. In previous works, we have described CD24 as a new prognostic marker in solid tumors (3–6). Recently, CD24 has been shown to be a prognostic marker in gastric adenocarcinoma (7). CD24 is a small, heavily glycosylated, mucin-like cell surface protein (8–10). It is expressed in various developing cells including pre-B-cells, keratinocytes, and renal tubulus epithelium, and also in a large variety of malignancies (for a comprehensive review, see ref. 11). CD24 functions as an alternative ligand of P-selectin, an adhesion receptor expressed on activated endothelial cells and platelets, and could thus enhance the metastatic potential of CD24-expressing tumor cells (12–15). To date, only limited data on CD24 RNA expression in colon cancer have been published (16, 17) and, to our knowledge, no data on CD24 protein levels are available. We aimed to investigate the expression patterns of CD24 protein in colon cancer cell lines and human colorectal carcinomas and to correlate our findings to clinicopathologic variables including patient survival times.

Materials and Methods

Cell lines. The human colon adenocarcinoma cell line HT29 was obtained from American Type Culture Collection (Rockville, MD). The human colon adenocarcinoma cell line CX-2 was from the German Cancer Research Center (Heidelberg, Germany). Cells were cultured in RPMI supplemented with 10% fetal bovine serum.

Patients. One hundred forty-seven consecutive cases (age, 17 to 87 years; median, 65) who were diagnosed for colorectal cancer at the Institute of Pathology, Charité University Hospital, between 1996 and 1998 were enclosed in this study. Only patients with primary colorectal adenocarcinomas without neoadjuvant radiochemotherapy and no other known malignancies at the time of diagnosis and during follow-up were included. A small number of cases had to be excluded due to limited tissue availability. Histologic diagnosis was established on standard H&E-stained sections according to the guidelines of the WHO. The vast majority of patients with nodal positive colon cancer and patients with either nodal positive or locally advanced (pT3/pT4) rectal cancer received adjuvant chemotherapy with 5-fluorouracil and levamisole or 5-fluorouracil alone according to the guidelines of the German Cancer Society from 1994 (18). Clinical follow-up data were available for all patients. Forty-one (27.9%) patients died during follow-up with a median survival of 17 months. The median follow-up time of patients still alive at the end point of analysis was 53 months. Clinicopathologic variables are summarized in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Clinicopathologic characteristics of the colon cancer cohort

Immunofluorescence. Immunofluorescence staining was done according to standard procedures. Briefly, subconfluent cells grown on Labtek chamber slides (Nunc, Wiesbaden, Germany) were fixed in methanol for 10 minutes at −20°C. Slides were incubated with primary CD24 antibody (clone 32D12, Dianova, Hamburg, Germany) diluted 1:100 in PBS/1% bovine serum albumin for 90 minutes at 21°C, followed by incubation with a Cy3-conjugated anti-mouse antibody (Dianova) diluted 1:200 in PBS/1% bovine serum albumin. Confocal laser scanning microscopy was done using a Leica confocal microscope.

Immunohistochemistry. Formalin-fixed paraffin-embedded tissue was freshly cut (4 μm). The sections were mounted on superfrost slides (Menzel Gläser, Braunschweig, Germany), dewaxed with xylene, and gradually hydrated. Antigen retrieval was achieved by pressure cooking in 0.01 mol/L citrate buffer for 5 minutes. The primary CD24 antibody (Ab-2, clone 24C02/SN3b, Neomarkers, Fremont, CA) was diluted 1:100 using a background reducing dilution buffer (DAKO, Hamburg, Germany) and was incubated at room temperature for 1 hour. Detection took place by the conventional labeled streptavidin-biotin method (LSAB kit, DAKO) with alkaline phosphatase as the reporting enzyme according to the instructions of the manufacturer. Fast Red (Sigma-Aldrich, Munich, Germany) served as chromogen. Afterwards the slides were briefly counterstained with hematoxylin and aqueously mounted.

Immunostaining of tissue slides was independently evaluated by three clinical pathologists who were unaware of patient outcome. As CD24 showed a cytoplasmic and membranous staining, we scored both staining qualities as either negative or weakly, moderately, or strongly positive.

Statistical analysis. The data were compiled with the software package SPSS, version 12.0. Fisher's exact test, χ2 test, and χ2 test for trends were used to assess the statistical significance of associations between expression of CD24 and clinicopathologic variables. Univariate survival analysis was done according to Kaplan-Meier; differences in survival curves were assessed with the log-rank test. Multivariate survival analysis was done on all variables that were found to be significant on univariate analysis using Cox's regression model, having checked that no violation of the proportional hazards assumption became apparent in a visual evaluation of log(−log(survival)) plots. P < 0.05 was considered significant. All statistics were accredited by the head biostatistician of the Tumor Center, Charité University Hospital (J.B.).

Results

CD24 immunofluorescence. The cell line CX-2 showed a weak and only focal dot-like membranous CD24 immunoreactivity (Fig. 1A). In contrast, HT29 cells exhibited a strong homogeneous cytoplasmic and focal membranous immunostaining (Fig. 1B).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

CD24 immunofluorescence. A, CD24 expression is virtually absent in the colon cancer cell line CX-2. Note strong exclusively membranous expression in the ovarian carcinoma cell line OVCAR-3, which served as positive control (inset). B, strong cytoplasmic and focal membranous expression of CD24 in the HT29 colon cancer cell line.

CD24 immunohistochemistry and statistical analysis. As described in other organs, CD24 immunostainings showed two separable staining qualities in colon tissue, a membranous and a cytoplasmic immunoreactivity. Normal colon mucosa was virtually CD24 negative, although some cases exhibited a weak membranous staining at the brush border. In general, colorectal carcinomas showed higher levels of CD24 expression, often with a relatively abrupt up-regulation in the transition zone of normal mucosa to neoplastic epithelium (Fig. 2A and B). The distribution of immunoreactivity in the tumors was fairly homogeneous, which made the evaluation of the staining intensity straightforward (0, +, ++, +++), and allowed omittance to incorporate the percentage of positive tumor cells in an immunoreactivity score. Details are given in Tables 2 and 3; for membranous CD24 staining, 68.7% of tumors were positive and 17% were strongly positive. Higher rates of membranous CD24 immunoreactivity were associated with systemic metastasis (pM1) but showed no significant correlation to other clinicopathologic variables (Table 2). For cytoplasmic CD24 staining, we found 84.4% of cases positive and 10.2% cases showing a strong expression (Table 3). Cytoplasmic CD24 immunoreactivity was significantly associated with higher tumor stages (Dukes and pT), nodal or systemic metastasis (pN and pM), and finally tumor grade.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

CD24 immunohistochemistry. A, transition of low-grade dysplastic colonic epithelium in colon carcinoma. Note abrupt onset of predominantly membranous expression of CD24. B, interface between colon mucosa and colon carcinoma. Note strong predominantly cytoplasmic overexpression of CD24 in the neoplastic glands of this case. C, colon cancer with minimal focal membranous expression of CD24 (arrows). D, colon cancer with strong membranous expression of CD24 without cytoplasmic positivity. E, neoplastic colonic glands with strong cytoplasmic CD24 expression. F, liver metastasis of a colon carcinoma from the study cohort. Note strong simultaneous cytoplasmic and membranous expression of CD24.

View this table:
  • View inline
  • View popup
Table 2.

Associations between membranous CD24 expression and clinicopathologic variables

View this table:
  • View inline
  • View popup
Table 3.

Associations between cytoplasmic CD24 expression and clinicopathologic variables

Survival analysis. Cases with a strong cytoplasmic CD24 positivity showed a significantly shortened mean survival time in comparison with the other patients (P = 0.0018; Fig. 3A). This was even more evident in the group of non-pM1 patients (P = 0.0003; Fig. 3B). In contrast, no association of membranous CD24 expression with patient survival times was demonstrable (Table 4; Fig. 3C).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Patient survival in dependence of CD24 expression pattern. A and B, Kaplan-Meier survival curves for patients grouped for cytoplasmic CD24 expression (A, whole study cohort; B, patients without distant metastasis). Note dramatically reduced survival time for those patients whose tumors showed strong cytoplasmic positivity. C, survival curves for patients grouped for membranous CD24 expression.

View this table:
  • View inline
  • View popup
Table 4.

Univariate survival analysis of CD24 expression and clinicopathologic variables

Other prognostic factors in univariate survival analysis were Dukes stage, WHO tumor stage, nodal status, state of distant metastasis, and tumor grade (Table 4). Tumor localization was only a significant survival factor when the cases were grouped as either rectal or nonrectal carcinomas (P = 0.01). This is due to the tendency towards lower stages in our subgroup of rectal carcinomas, which is an effect of the exclusion of advanced rectal carcinomas treated with neoadjuvant therapy before operation.

In the multivariate survival analysis of the group of patients without distant metastasis, cytoplasmic CD24 expression remained a significant independent prognostic factor (P = 0.012) with a relative risk of 3.7 (confidence interval, 1.3-10.3). Other independent prognostic factors in multivariate survival analysis were the extent of tumor spread to the regional lymph nodes and patient age (Table 5). The prognostic value of strong cytoplasmic CD24 expression failed significance if all patients, including pM1 cases, were analyzed (data not shown).

View this table:
  • View inline
  • View popup
Table. 5.

Cox regression analysis of cases without distant metastasis (n = 135)

Discussion

CD24 is a small, glycosylated, mucin-like glycosylphosphatidylinositol-linked cell surface protein that is expressed physiologically in the developing pancreas and brain (19, 20), in regenerating muscle (21), and in normal keratinocytes (22) and renal tubules (23). Its physiologic function is not fully elucidated, but it seems to be involved in control of cell proliferation, apoptosis, and cell adhesion. Overexpression of CD24 in lymphocytes suggested that CD24 levels can modulate the capacity of early T and B lymphoid progenitor cells to proliferate and survive. Antibody-based studies showed that cross-linking of CD24 induced apoptosis in B-cell precursors and suppressed the anti-CD40–induced proliferation of mature resting B lymphocytes (24). More recently, induction of apoptosis via CD24 was found in human Burkitt's lymphoma cells (25).

To date, the only CD24 ligand that has been identified is P-selectin. CD24 was able to support the adhesion of neutrophils or monocytes to activated endothelial cells or platelets, both of which express P-selectin. Additionally, this binding could be blocked by antibodies to P-selectin or CD24 (12). There is evidence suggesting a prometastatic role of CD24 in human tumor cells, which is based on this CD24-P-selectin interaction (13). Physiologically, P-selectin is expressed by activated endothelial cells and platelets and plays an important role in marginal adhesion and migration of cells under shear forces in the blood stream (12). Thus, it is conceivable that CD24-expressing tumor cells can disseminate more easily due to their capacity to form thrombi with activated platelets or to adhere to endothelia in the bloodstream, which has been showed for CD24-expressing breast cancer cells (15). In fact, we could show faster rates of disease progression of CD24-positive primary tumors for a variety of solid malignancies.

To our knowledge, this is the first comprehensive description of CD24 protein expression in colorectal carcinomas. In previous studies using the same methods, we have analyzed CD24 expression in epithelial ovarian cancer, breast cancer, non–small-cell lung cancer, prostate cancer, and pancreatic cancer (3–6, 26). With the exception of pancreatic cancer, we were able to show a significant association of higher CD24 levels in these tumors with earlier disease progression or earlier disease–related death. The definitions of CD24 expression rates and qualities to delineate low- and high-risk groups were slightly variable in these studies, but basically CD24-negative tumors were opposed to CD24-positive ones. Therefore, it is surprising to learn that in colorectal cancer, only the group with exceptionally strong cytoplasmic CD24 staining, which comprises 10% of cases in our study, suffered a markedly shortened survival, whereas the Kaplan-Meier curves for the other tumors did not differ significantly. Although we have noted in earlier studies that the cytoplasmic CD24 staining pattern is prognostically more significant than the membranous staining, the biological significance of cytoplasmic CD24 expression remains unclear. It could hint at an overproduction of CD24, at disturbances of CD24 distribution in the cell, or both. Very recently, Choi et al. (27) could reproduce our finding of cytoplasmic CD24 as a prognostic marker in epithelial ovarian cancer. More importantly, they investigated a larger cohort of ovarian borderline tumors and could clearly link cytoplasmic CD24 immunoreactivity to microinvasion. Apparently, the shift from apical membranous CD24 localization, which is observed in normal cells and in cells of very well differentiated glandular tumors, to the cytoplasmic CD24 localization reflects the transition of epithelial cells to a more invasive phenotype. This is reminiscent of the well-known epithelial-mesenchymal transition of tumor cells which is associated with the onset of invasiveness. In the cytoplasm, CD24 is stored in microvesicular bodies, which can be shed by tumor cells as exosomes into the environment and circulation.4

Linked to the cell membrane by a glycosylphosphatidylinositol anchor, CD24 is physiologically localized in lipid rafts, which represent small membrane microdomains serving as a platform for the regulation of cell adhesion and signaling (28). Within rafts, HSA/CD24 is closely associated with src kinases, G proteins, and calcium channels. Signal transduction via Tyr phosphorylation and src kinases has been described on triggering of many glycosylphosphatidylinositol-anchored molecules (29) but a specific signaling cascade for CD24 has not yet been identified, which ought to be the focus of further study.

The finding of cytoplasmic CD24 as an independent marker of high-risk patients is important, although the group of patients with strongly CD24-expressing colorectal cancers is comparatively small. This information could assist us in our attempt to individualize patient care (e.g., monitoring more closely the patients under concern for disease recurrence or progression after surgery) or even to consider an intensified adjuvant therapy.

In summary, we found CD24 overexpression in neoplastic colonic epithelia of carcinomas. Moreover, strong cytoplasmic CD24 expression was associated with shortened patient survival times in univariate and multivariate analyses, which clearly warrants further studies to clarify the biological role of CD24 in colorectal cancer.

Acknowledgments

The excellent technical assistance of Britta Beyer and Lisa Glanz is gratefully acknowledged. Thanks to Ilka Olson and Alfred E. Neumann for helpful discussions.

Footnotes

  • ↵4 Altevogt et al., unpublished data.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 22, 2005.
    • Received March 18, 2005.
    • Revision received June 6, 2005.

References

  1. ↵
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
    OpenUrlCrossRefPubMed
  2. ↵
    McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191–203.
    OpenUrlPubMed
  3. ↵
    Kristiansen G, Denkert C, Schluns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215–21.
    OpenUrlCrossRefPubMed
  4. Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183–92.
    OpenUrlCrossRefPubMed
  5. Kristiansen G, Schluns K, Yongwei Y, et al. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br J Cancer 2003;88:231–6.
    OpenUrlCrossRefPubMed
  6. ↵
    Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003;9:4906–13.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Darwish NS, Kim MA, Chang MS, et al. Prognostic Significance of CD24 Expression in Gastric Carcinoma. Cancer Res Treat 2004;5:298–302.
    OpenUrl
  8. ↵
    Pirruccello SJ, LeBien TW. The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986;136:3779–84.
    OpenUrlAbstract
  9. Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990;144:638–41.
    OpenUrlAbstract
  10. ↵
    Akashi T, Shirasawa T, Hirokawa K. Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch 1994;425:399–406.
    OpenUrlPubMed
  11. ↵
    Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255–62.
    OpenUrlCrossRefPubMed
  12. ↵
    Aigner S, Ruppert M, Hubbe M, et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995;7:1557–65.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385–95.
    OpenUrlAbstract/FREE Full Text
  14. Sammar M, Aigner S, Hubbe M, et al. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol 1994;6:1027–36.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Aigner S, Ramos CL, Hafezi-Moghadam A, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12:1241–51.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001;61:1569–77.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Saito A, Fujii G, Sato Y, et al. Detection of genes expressed in primary colon cancers by in situ hybridisation: overexpression of RACK 1. Mol Pathol 2002;55:34–9.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Pichlmaier H, Hossfeld DK, Sauer R. Konsensus der CAO, AIO und ARO zur adjuvanten Therapie bei Kolon und Rektumkarzinom vom 11.03.1994. Chirurg 1994;65:411–2.
    OpenUrl
  19. ↵
    Cram DS, McIntosh A, Oxbrow L, Johnston AM, DeAizpurua HJ. Differential mRNA display analysis of two related but functionally distinct rat insulinoma (RIN) cell lines: identification of CD24 and its expression in the developing pancreas. Differentiation 1999;64:237–46.
    OpenUrlCrossRefPubMed
  20. ↵
    Shirasawa T, Akashi T, Sakamoto K, et al. Gene expression of CD24 core peptide molecule in developing brain and developing non-neural tissues. Dev Dyn 1993;198:1–13.
    OpenUrlPubMed
  21. ↵
    Figarella-Branger D, Moreau H, Pellissier JF, Bianco N, Rougon G. CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol (Berl) 1993;86:275–84.
    OpenUrlCrossRefPubMed
  22. ↵
    Redondo P, Garcia-Foncillas J, Okroujnov I, de Felipe I, Quintanilla E. CD24 expression on human keratinocytes. Exp Dermatol 1998;7:175–8.
    OpenUrlPubMed
  23. ↵
    Droz D, Zachar D, Charbit L, et al. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 1990;137:895–905.
    OpenUrlPubMed
  24. ↵
    Chappel MS, Hough MR, Mittel A, et al. Cross-linking the murine heat-stable antigen induces apoptosis in B cell precursors and suppresses the anti-CD40-induced proliferation of mature resting B lymphocytes. J Exp Med 1996;184:1638–49.
  25. ↵
    Suzuki T, Kiyokawa N, Taguchi T, et al. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001;166:5567–77.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Jacob J, Bellach J, Grutzmann R, et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 2004;4:454–60.
    OpenUrlCrossRefPubMed
  27. ↵
    Choi YL, Kim SH, Shin YK, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol 2005;97:379–86.
    OpenUrlCrossRefPubMed
  28. ↵
    Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569–72.
    OpenUrlCrossRefPubMed
  29. ↵
    Jacobson K, Dietrich C. Looking at lipid rafts? Trends Cell Biol 1999;9:87–91.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 11 (18)
September 2005
Volume 11, Issue 18
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel and Glen Kristiansen
Clin Cancer Res September 15 2005 (11) (18) 6574-6581; DOI: 10.1158/1078-0432.CCR-05-0606

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel and Glen Kristiansen
Clin Cancer Res September 15 2005 (11) (18) 6574-6581; DOI: 10.1158/1078-0432.CCR-05-0606
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TP53 in Breast Cancer
  • FDOPA PET Survival Predictions for Glioma
  • In vivo Fluorescence Lifetime Imaging for Monitoring the Cancer Treatment
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement